Research Topics
Species | Tanios Bekaii-SaabSummaryAffiliation: The Ohio State University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancersTanios Bekaii-Saab
The Ohio State University Comprehensive Cancer Center James Cancer Hospital and Solove Research Institute, Columbus, OH 43210, USA
J Clin Oncol 29:2357-63. 2011..Selumetinib is an inhibitor of MEK1/2, so this trial was designed to determine the safety and efficacy of selumetinib in BC...- A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinomaTanios Bekaii-Saab
Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA
BMC Cancer 6:278. 2006..In our study, we sought to determine if similar respective gain-of-function EGFR and ERBB2 mutations were present in hepatoma and/or biliary cancers... - A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomasTanios Bekaii-Saab
The Ohio State University Comprehensive Cancer Center, Columbus, Ohio 43210, USA
Clin Cancer Res 15:5895-901. 2009..HCC responds poorly to chemotherapy. Lapatinib is an inhibitor of epidermal growth factor receptor and HER2/NEU both implicated in hepatocarcinogenesis. This trial was designed to determine the safety and efficacy of lapatinib in HCC... 
A phase I dose escalation study of a pharmacobiologically based scheduling of capecitabine and mitomycin C in patients with gastrointestinal malignanciesTanios Bekaii-Saab
The Ohio State University Comprehensive Cancer Center, B407 Starling Loving Hall, 320 West 10th Avenue, Columbus, OH 43210, USA
Cancer Chemother Pharmacol 65:863-9. 2010..On the basis of the time-dependency of this upregulation, we performed a phase I dose escalation study of capecitabine and MMC in patients with gastrointestinal malignancies...- KRAS testing in metastatic colorectal cancer: implications on the use of biologic agentsTanios Bekaii-Saab
Department of Medicine, Division of Hematology and Oncology, The Ohio State University Arthur James Cancer Hospital, Columbus, OH 43210 1240, USA
Clin Colorectal Cancer 8:135-40. 2009..These findings are likely to change the landscape of metastatic CRC treatment by providing an improved patient-tailored approach... - A phase I study of the biomodulation of capecitabine by docetaxel and gemcitabine (mGTX) in previously untreated patients with metastatic adenocarcinoma of the pancreasMarisa E Hill
Ohio State University Comprehensive Cancer Center, Arthur James Cancer Hospital, Columbus, OH, 43210, USA
Cancer Chemother Pharmacol 67:511-7. 2011..Pancreas cancer remains a formidable challenge. We report the first prospective analysis of the 3-drug combination of gemcitabine (G), docetaxel (T) and capecitabine (X) (mGTX) with schedule modification to maximize biomodulation of X... - Influence of KRAS mutation status in metachronous and synchronous metastatic colorectal adenocarcinomaJeffrey S Rose
Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Medical Center, Columbus, Ohio 43210, USA
Cancer 118:6243-52. 2012..The prognostic value of KRAS in metastatic disease, specifically according to whether patients have synchronous or metachronous disease at presentation, is less understood... - HER2/neu may not be an interesting target in biliary cancers: results of an early phase II study with lapatinibJoshua Peck
The Ohio State University Comprehensive Cancer Center, James Cancer Hospital and Solove Research Institute, Columbus, Ohio, USA
Oncology 82:175-9. 2012..Lapatinib is a dual inhibitor of epidermal growth factor receptor (EGFR) and HER2/neu, both implicated in cholangiocarcinogenesis. This trial was designed to determine the safety and efficacy of lapatinib in BC... - A dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumorsBhuvaneswari Ramaswamy
Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH, USA
Invest New Drugs 30:629-38. 2012.... - Phase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancerElaine T Lam
Department of Internal Medicine, Division of Hematology and Oncology, The Ohio State University, Columbus, OH 43210 1240, USA
Cancer Chemother Pharmacol 66:1019-29. 2010..The present study evaluated the safety and tolerability of suramin in combination with docetaxel or gemcitabine in previously chemotherapy-treated patients with advanced non-small cell lung cancer... - Phase II randomized study of two regimens of sequentially administered mitomycin C and irinotecan in patients with unresectable esophageal and gastroesophageal adenocarcinomaMaryam B Lustberg
Department of Internal Medicine, Ohio State University College of Medicine and Public Health, Columbus, Ohio 43210 1240, USA
J Thorac Oncol 5:713-8. 2010.... - Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: a pooled analysis of 6 prospective trialsTodd M Bauer
Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio 43210, USA
Cancer 119:285-92. 2013..Carbohydrate antigen 19-9 (CA19-9) is a widely used biomarker in pancreatic cancer. There is no consensus on the interpretation of the change in CA19-9 serum levels and its role in the clinical management of patients with pancreatic cancer... - A dose escalation and pharmacodynamic study of triapine and radiation in patients with locally advanced pancreas cancerLudmila Katherine Martin
Department of Internal Medicine, The Ohio State University, Columbus, Ohio 43210, USA
Int J Radiat Oncol Biol Phys 84:e475-81. 2012.... - STAT3 signaling pathway is necessary for cell survival and tumorsphere forming capacity in ALDH⁺/CD133⁺ stem cell-like human colon cancer cellsLi Lin
Center for Childhood Cancer, The Research Institute at Nationwide Children s Hospital, Department of Pediatrics, Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH 43205, USA
Biochem Biophys Res Commun 416:246-51. 2011..In summary, our results indicate that STAT3 is a novel therapeutic target in colon cancer stem-like cells and inhibition of STAT3 in cancer stem-like cells may offer a potential treatment for colorectal cancer... - Yttrium-90 radioembolization as salvage therapy for colorectal cancer with liver metastasesLudmila Katherine Martin
Division of Hematology, Department of Internal Medicine, The Ohio State University Medical Center, Columbus, OH, USA
Clin Colorectal Cancer 11:195-9. 2012..Yttrium-90 ((90)Y) radioembolization has promise in the treatment of unresectable mCRC. We conducted a retrospective study to assess the efficacy in patients with refractory mCRC who underwent (90)Y radioembolization... - Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trialAllyson J Ocean
Department of Medicine, Division of Hematology and Medical Oncology, New York Presbyterian Hospital, Weill Medical College of Cornell University, New York, New York 10021, USA
Cancer 118:5497-506. 2012.... - A phase I study of topotecan and gemcitabine in advanced solid tumorsDerek S Serna
Division of Hematology and Oncology, The Ohio State University, Columbus, OH 43210, USA
Invest New Drugs 29:1390-4. 2011..Synergism has been demonstrated in vitro when gemcitabine and other topoisomerase I inhibitors have been combined... - Capped-dose mitomycin C: a pooled safety analysis from three prospective clinical trialsNse Ntukidem
Department of Medicine, The Ohio State University, Columbus, USA
Cancer Chemother Pharmacol 65:319-24. 2010..One of the most devastating toxicities MMC has been associated with is thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS) in 4-15% of patients, especially when receiving cumulative doses higher than 60 mg/m(2)... - Antiemetic control with palonosetron in patients with gastrointestinal cancer receiving a fluoropyrimidine-based regimen in addition to either irinotecan or oxaliplatin: a retrospective studyMarlo Blazer
Arthur G James Cancer Hospital and Richard J Solove Research Institute, The Ohio State University, Columbus, Ohio 43212, USA
Oncology 83:135-40. 2012..Beginning in August of 2009, ondansetron was replaced by PALO 0.25 mg (intravenous push)... - A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumorsBhuvaneswari Ramaswamy
The Ohio State University, B401, Starling Loving Hall, 320 W 10th av, Columbus, OH 43210, USA
Cancer Chemother Pharmacol 66:151-8. 2010..A phase I study to determine the maximum tolerated dose (MTD) of bortezomib (B) when combined with weekly paclitaxel in patients with advanced solid tumors... - A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumorsAmir Mortazavi
Division of Medical Oncology, Department of Internal Medicine, College of Medicine, The Ohio State University and the Comprehensive Cancer Center, A454 Starling Loving Hall, 320 West 10th Ave, Columbus, OH, 43210, USA
Invest New Drugs 31:685-95. 2013..Conclusions This combination was well tolerated and showed evidence of preliminary activity in this heavily pretreated patient population, including prior gemcitabine failure... - Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4⁺ T cells from patients with GI malignancyBethany L Mundy-Bosse
Department of Integrated Biomedical Sciences, The Ohio State University, Columbus, OH, USA
Cancer Immunol Immunother 60:1269-79. 2011..033). These data provide evidence for a unique relationship between specific cytokines, MDSC subsets, and IFN-α responsiveness in patients with GI malignancies... 
An update on biochemotherapy of advanced gastric and gastroesophageal adenocarcinomaPeyman Haghighat
Department of Medicine, Division of Hematology and Oncology, Arthur G James Cancer Hospital, The Ohio State University, Columbus, Ohio 43210 1240, USA
J Natl Compr Canc Netw 6:895-900. 2008..This article reviews current active chemotherapeutic regimens and explores the role of novel targeted therapies in advanced GGA...- Phase II trial of pyrazoloacridine (NSC#366140) in patients with metastatic breast cancerBhuvaneswari Ramaswamy
Division of Hematology and Oncology, Ohio State University Medical Center, Arthur G James Cancer Hospital and Richard J Solove Research Institute, Columbus, OH 43210, USA
Invest New Drugs 29:347-51. 2011..We conducted a phase II clinical study to determine the efficacy and toxicities of PZA in patients with metastatic breast cancer (MBC). Experimental.. - A phase II study of modulated-capecitabine and docetaxel in chemonaive patients with advanced non-small cell lung cancer (NSCLC)Erin M Bertino
The Ohio State University Wexner Medical Center, Department of Internal Medicine, Division of Medical Oncology, Columbus, OH, USA
Lung Cancer 79:27-32. 2013..The trial also evaluated the correlation between peripheral blood dihydropyrimidine dehydrogenase (DPD) expression and efficacy/toxicity... - Elevated baseline CA19-9 levels correlate with adverse prognosis in patients with early- or advanced-stage pancreas cancerLudmila Katherine Martin
Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, M365 Starling Loving Hall, 320 West 10th Avenue, Columbus, OH 43210, USA
Med Oncol 29:3101-7. 2012..CA19-9 level decrease of >25 % predicts improved survival in advanced disease on chemotherapy... - Photodynamic Therapy (PDT) May Provide Effective Palliation in the Treatment of Primary Tracheal Carcinoma: A Small Case SeriesLudmila Katherine Martin
The Ohio State University James Cancer Hospital, Columbus, Ohio
Photomed Laser Surg 30:668-71. 2012..Conclusions: PDT is safe and provides effective palliation of obstructive symptoms in patients with primary tracheal carcinoma. PDT has a potential role in both the curative and the palliative setting... - Optimizing neoadjuvant therapy for rectal cancer with oxaliplatinLudmila Katherine Martin
Department of Internal Medicine, Division of Medical Oncology, Section of Gastrointestinal Oncology, The Ohio State University Medical Center, Columbus Ohio, USA
J Natl Compr Canc Netw 11:298-307; quiz 307. 2013..This article reviews the existing literature and explores the potential role of oxaliplatin as part of neoadjuvant CRT for rectal cancer... - Management of venous thromboembolism in patients with advanced gastrointestinal cancers: what is the role of novel oral anticoagulants?Ludmila Katherine Martin
Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Medical Center, M365 Starling Loving Hall, 410 W 10th Avenue, Columbus, OH 43210, USA
Thrombosis 2012:758385. 2012..This paper reviews the existing efficacy and safety data for the use of NOAs dabigatran etexilate, rivaroxaban, and apixaban and discusses the potential role of these agents in the management of gastrointestinal cancer-related VTE... - Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis: a case reportBrian J So
The Ohio State University Medical Center, 395 W, 12th Avenue, Columbus, OH 43210, USA
J Hematol Oncol 1:18. 2008..No evidence of disease recurrence has been noted for 6 months after discontinuation of therapy... - Curcumin analogues exhibit enhanced growth suppressive activity in human pancreatic cancer cellsLauren Friedman
Department of Pediatrics, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University, Columbus, OH 43205, USA
Anticancer Drugs 20:444-9. 2009.... - Hepatobiliary cancers. Clinical practice guidelines in oncologyAl B Benson
Robert H. Luri Comprehensive Cancer Center of Northwestern University
J Natl Compr Canc Netw 4:728-50. 2006